A Study of ARC-02 in B-cell NHL

This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.

Trial Details

NCT ID
NCT07691606
Phase
PHASE1
Sponsor
Taiho Oncology, Inc.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • ARC-02
  • Rituximab
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Louisville, Kentucky, United States|38.25424,-85.75941
  • New York, New York, United States|40.71427,-74.00597
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Richmond, Virginia, United States|37.55376,-77.46026

Key Eligibility Criteria

  • A documented diagnosis of B-cell Non- Hodgkin Lymphoma (NHL) per 2016 World Health Organization criteria and disease requiring treatment:
  • Follicular lymphoma (FL), Grades 1 through 3B
  • Marginal zone lymphoma (MZL)
  • Mantle cell lymphoma (MCL)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →